- Drug development company Nyrada (NYR) has partnered with the Walter Reed Army Institute of Research and UNSW Sydney for a preclinical program
- The two-year program will examine whether Nyrada’s neuroprotection compound drug can mitigate the effects of traumatic brain injury
- In the U.S., 2.8 million people suffer TBI each year and, aside from neurosurgery and rehabilitation, there aren’t any treatments for the condition
- Further, military service members face the risk of TBI, with over 200,000 U.S. military service members diagnosed between 2000 and 2011
- The collaboration will also begin this month and study results expected within 12 months
- Nyrada down 3.85 percent and shares trading at 37.5 cents
